MedTrace Logo

The Intelligent Diabetes TelemonitoRing Using Decision Support to Treat Patients on Insulin Therapy

NCT06185296 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2026-02-09

No results posted yet for this study

Summary

The trial is an open-label, randomized controlled trial. Patients with T2D on insulin therapy will be randomized to an intelligent telemonitoring group (intervention), a telemonitoring group (control), and a usual care group (control). Both the intelligent telemonitoring group and the telemonitoring group will use various devices at home. Hospital staff will monitor their data for three months. In the intelligent telemonitoring group, hospital staff and participants will be supported by decision-support algorithms in the management of insulin treatment.

Conditions

  • Type 2 Diabetes Treated With Insulin

Interventions

DEVICE

Intelligent telemonitoring

Telemonitoring using CGM, insulin pen data, and Fitbit data supported by data-driven decision support.

DEVICE

Telemonitoring

Telemonitoring using CGM, insulin pen data, and Fitbit data

Sponsors & Collaborators

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • DexCom, Inc.

    collaborator INDUSTRY

  • Aalborg University Hospital

    lead OTHER

Principal Investigators

  • Peter Vestergaard, MD, PhD · Steno Diabetes Center North Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-15
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06185296 on ClinicalTrials.gov